PMC:4143611 / 7446-8340 JSONTXT

{"project":"2_test","denotations":[{"id":"24980037-9435417-63233424","span":{"begin":363,"end":365},"obj":"9435417"},{"id":"24980037-16304985-63233424","span":{"begin":363,"end":365},"obj":"16304985"},{"id":"24980037-2843068-63233424","span":{"begin":363,"end":365},"obj":"2843068"},{"id":"24980037-10366371-63233424","span":{"begin":363,"end":365},"obj":"10366371"},{"id":"24980037-8675592-63233425","span":{"begin":401,"end":403},"obj":"8675592"},{"id":"24980037-21918830-63233426","span":{"begin":748,"end":750},"obj":"21918830"}],"text":"There are conflicting data relating to whether it is possible to identify patients who may be at greater risk for recurrence of CD following pituitary surgery. For instance, there is some evidence that tumor size, age, and gender may predict long-term outcome following surgery, and that the likelihood of recurrence may be higher in patients with macroadenomas [22–25], and patients who are younger [26]. However, a thorough review and meta-analysis of various predictive factors of recurrence found that age, gender, tumor size, and macroscopic tumor invasion were not associated with CD recurrence, whereas low levels of cortisol immediately following surgery appeared to be a positive predictor of long-term remission in more reports than not [27]. Therefore, it is unclear to what extent recurrence can be predicted, highlighting the importance of regular post-surgical patient monitoring."}